Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 08:30 ET | Source: DENTSPLY SIRONA Inc.

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics

Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United...
March 06, 2026 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
March 05, 2026 08:00 ET | Source: Advantage Healthcare & Physiotherapy

Advantage Healthcare & Physiotherapy Expands Premier Women’s Health Services in Wynnum with Senior Clinical Appointment

Brisbane, QLD, March 05, 2026 (GLOBE NEWSWIRE) -- Advantage Healthcare & Physiotherapy is proud to announce a significant expansion of its clinical team and specialized service offerings with...
March 05, 2026 05:55 ET | Source: AnalystView Market Insights

From Lab Innovation to Life-Saving Therapies: Gene Editing Therapeutics Market Poised to Hit US$ 6.26 Billion by 2032, Expanding at a 147.20% CAGR Driven by Rapid CRISPR Breakthrough: AnalystView Market Insights

Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.
March 04, 2026 10:25 ET | Source: Can-Fite BioPharma Ltd.

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of...
March 04, 2026 07:00 ET | Source: Can-Fite BioPharma Ltd.

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small...
March 03, 2026 09:00 ET | Source: PharmAla Biotech

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

Pharmala announces a newly signed contract to supply a clinical trial, and the fulfillment of a previously announced trial.
March 02, 2026 11:45 ET | Source: VALNEVA

Valneva to Participate in Upcoming Investor Conferences

Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming...
March 02, 2026 06:00 ET | Source: RadNet, Inc.

RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health...
February 28, 2026 09:45 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase...